A Case of Sequential Development of Polymyalgia Rheumatica and Guillain-Barré Syndrome Following Administration of the Pfizer-BioNTech COVID-19 Vaccine

Intern Med. 2022 Oct 1;61(19):2995. doi: 10.2169/internalmedicine.0319-22. Epub 2022 Jul 22.

Authors

Shunsuke Yamada^{1

2}, Kanako Yamada¹, Hiroshi Nishida¹

Affiliations

¹ Nishida Hospital, Japan.
² Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan.

No abstract available

Keywords: COVID-19; Guillain-Barré syndrome; polymyalgia rheumatica; vaccine.

Publication types

Case Reports

MeSH terms

BNT162 Vaccine
COVID-19*
Giant Cell Arteritis*
Guillain-Barre Syndrome* / chemically induced
Humans
Influenza Vaccines*
Polymyalgia Rheumatica*

Substances

Influenza Vaccines
BNT162 Vaccine